What is the primary first line pharmaceutical agent used to treat Coccidioidomycosis immitis (Valley Fever) in companion animals?

What is the primary first line pharmaceutical agent used to treat Coccidioidomycosis immitis (Valley Fever) in companion animals?

• A. Fluconazole
• B. Itraconazole
• C. Ketoconazole
• D. Terbinafine

Answer: (A)

Valley Fever in dogs and cats is treated with drugs that slow the fungus by inhibiting ergosterol synthesis, allowing the animal’s own defenses to control the infection over long periods. Fluconazole is often chosen first because it has excellent oral bioavailability and reaches good levels in many tissues, including the central nervous system and eyes, which is important since disseminated coccidioidomycosis can involve those areas. It’s generally well tolerated and carries a lower risk of liver toxicity compared with older azoles, making long-term therapy safer and easier to manage. It also tends to be simpler to dose consistently since its absorption is less dependent on stomach acidity than itraconazole, and it has fewer drug interactions. Itraconazole can be very effective but has more variable absorption that depends on gastric acidity and can cause more hepatotoxicity and drug interactions, which makes it a strong alternative but not the default first choice. Ketoconazole carries more hepatotoxic risk and endocrine effects, so it’s less favored. Terbinafine is useful in some cases or as adjunctive therapy but is not typically the primary agent for systemic coccidioidomycosis.

Valley Fever in dogs and cats is treated with drugs that slow the fungus by inhibiting ergosterol synthesis, allowing the animal’s own defenses to control the infection over long periods. Fluconazole is often chosen first because it has excellent oral bioavailability and reaches good levels in many tissues, including the central nervous system and eyes, which is important since disseminated coccidioidomycosis can involve those areas. It’s generally well tolerated and carries a lower risk of liver toxicity compared with older azoles, making long-term therapy safer and easier to manage. It also tends to be simpler to dose consistently since its absorption is less dependent on stomach acidity than itraconazole, and it has fewer drug interactions.

Itraconazole can be very effective but has more variable absorption that depends on gastric acidity and can cause more hepatotoxicity and drug interactions, which makes it a strong alternative but not the default first choice. Ketoconazole carries more hepatotoxic risk and endocrine effects, so it’s less favored. Terbinafine is useful in some cases or as adjunctive therapy but is not typically the primary agent for systemic coccidioidomycosis.